Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/2/422 |
id |
doaj-c9e2c81bee804be9abf99db428b19ea0 |
---|---|
record_format |
Article |
spelling |
doaj-c9e2c81bee804be9abf99db428b19ea02020-11-25T02:17:32ZengMDPI AGJournal of Clinical Medicine2077-03832020-02-019242210.3390/jcm9020422jcm9020422Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series StudyAndrea Vianello0Francesco Salton1Beatrice Molena2Cristian Turato3Maria Laura Graziani4Fausto Braccioni5Valeria Frassani6Dino Sella7Paolo Pretto8Luciana Paladini9Andi Sukthi10Marco Confalonieri11Respiratory Pathophysiology Unit, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, 35128 Padova, ItalyPneumology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyRespiratory Pathophysiology Unit, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, 35128 Padova, ItalyVeneto Institute of Oncology IOV–IRCCS, 35128 Padova, ItalyPneumology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyRespiratory Pathophysiology Unit, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, 35128 Padova, ItalyPneumology Unit, Arco General Hospital, APSS Trento, 38062 Arco, ItalyPneumology Unit, Trento General Hospital, Trento, APSS Trento, 38121 Trento, ItalyPulmonology Unit, AS Bolzano, 39100 Bolzano, ItalyRespiratory Pathophysiology Unit, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, 35128 Padova, ItalyRespiratory Pathophysiology Unit, Department of Cardiological, Thoracic and Vascular Sciences, University of Padova, 35128 Padova, ItalyPneumology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, ItalyBackground: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-line treatment in subjects who have discontinued pirfenidone. Methods: The medical charts of 12 patients who were switched from pirfenidone to nintedanib were examined retrospectively. The drug’s safety was defined by the number of adverse events (AEs) that were reported; disease progression was evaluated based on the patient’s vital status and changes in forced vital capacity (FVC) at 12-month follow-up. Results: The numbers of patients experiencing AEs and of the AEs per patient in our study group didn’t significantly differ with respect to a group of 56 individuals who were taking nintedanib as a first-line therapy during the study period (5/12 vs. 22/56; <i>p</i> = 0.9999, and 0.00 (0.00−1.00) vs. 0.00 (0.00−3.00); <i>p</i> = 0.517, respectively). Two out of the 3 patients who had been switched to nintedanib due to a rapid disease progression showed stabilized FVC values. Conclusions: Nintedanib was found to have an acceptable safety profile in the majority of the IPF patients switched from pirfenidone. Prospective studies are warranted to determine if the drug can effectively delay disease progression in these patients.https://www.mdpi.com/2077-0383/9/2/422idiopathic pulmonary fibrosispirfenidonenintedanibadverse eventforced vital capacity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andrea Vianello Francesco Salton Beatrice Molena Cristian Turato Maria Laura Graziani Fausto Braccioni Valeria Frassani Dino Sella Paolo Pretto Luciana Paladini Andi Sukthi Marco Confalonieri |
spellingShingle |
Andrea Vianello Francesco Salton Beatrice Molena Cristian Turato Maria Laura Graziani Fausto Braccioni Valeria Frassani Dino Sella Paolo Pretto Luciana Paladini Andi Sukthi Marco Confalonieri Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study Journal of Clinical Medicine idiopathic pulmonary fibrosis pirfenidone nintedanib adverse event forced vital capacity |
author_facet |
Andrea Vianello Francesco Salton Beatrice Molena Cristian Turato Maria Laura Graziani Fausto Braccioni Valeria Frassani Dino Sella Paolo Pretto Luciana Paladini Andi Sukthi Marco Confalonieri |
author_sort |
Andrea Vianello |
title |
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study |
title_short |
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study |
title_full |
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study |
title_fullStr |
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study |
title_full_unstemmed |
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study |
title_sort |
nintedanib treatment for idiopathic pulmonary fibrosis patients who have been switched from pirfenidone therapy: a retrospective case series study |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-02-01 |
description |
Background: The efficacy and effectiveness of nintedanib as a first-line therapy in idiopathic pulmonary fibrosis (IPF) patients have been demonstrated by clinical trials and real-life studies. Our aim was to examine the safety profile and effectiveness of nintedanib when it is utilized as a second-line treatment in subjects who have discontinued pirfenidone. Methods: The medical charts of 12 patients who were switched from pirfenidone to nintedanib were examined retrospectively. The drug’s safety was defined by the number of adverse events (AEs) that were reported; disease progression was evaluated based on the patient’s vital status and changes in forced vital capacity (FVC) at 12-month follow-up. Results: The numbers of patients experiencing AEs and of the AEs per patient in our study group didn’t significantly differ with respect to a group of 56 individuals who were taking nintedanib as a first-line therapy during the study period (5/12 vs. 22/56; <i>p</i> = 0.9999, and 0.00 (0.00−1.00) vs. 0.00 (0.00−3.00); <i>p</i> = 0.517, respectively). Two out of the 3 patients who had been switched to nintedanib due to a rapid disease progression showed stabilized FVC values. Conclusions: Nintedanib was found to have an acceptable safety profile in the majority of the IPF patients switched from pirfenidone. Prospective studies are warranted to determine if the drug can effectively delay disease progression in these patients. |
topic |
idiopathic pulmonary fibrosis pirfenidone nintedanib adverse event forced vital capacity |
url |
https://www.mdpi.com/2077-0383/9/2/422 |
work_keys_str_mv |
AT andreavianello nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT francescosalton nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT beatricemolena nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT cristianturato nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT marialauragraziani nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT faustobraccioni nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT valeriafrassani nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT dinosella nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT paolopretto nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT lucianapaladini nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT andisukthi nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy AT marcoconfalonieri nintedanibtreatmentforidiopathicpulmonaryfibrosispatientswhohavebeenswitchedfrompirfenidonetherapyaretrospectivecaseseriesstudy |
_version_ |
1724885786858356736 |